Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization

Sponsor
Bayer
Study ID
NCT02260687
Status
Completed

Conditions

  • Choroidal Neovascularization

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The objectives of this study are to investigate the safety and effectiveness of EYLEA.

Key Dates

Start date
Dec 5, 2014
Status verified
Sep 2019
Primary completion
Apr 2, 2018
Completion
Aug 22, 2018

Study Design

Enrollment
353 participants (actual)

Arms

  • Arm: Group 1
    Decision of treatment is made by attending investigator according to the Japanese Package Insert

Primary Outcome Measure

Number of episodes of Adverse drug reaction (ADR's) [ Time Frame: Up to 12 months ]

Related Studies